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Abstract The planning of IMRT treatments requires a compromise between dose
conformity (complexity) and deliverability. This study investigates established and
novel treatment complexity metrics for 122 IMRT beams from prostate treatment
plans. The Treatment and Dose Assessor software was used to extract the neces-
sary data from exported treatment plan files and calculate the metrics. For most
of the metrics, there was strong overlap between the calculated values for plans
that passed and failed their quality assurance (QA) tests. However, statistically
significant variation between plans that passed and failed QA measurements was
found for the established modulation index and for a novel metric describing the
proportion of small apertures in each beam. The ‘small aperture score’ provided
threshold values which successfully distinguished deliverable treatment plans from
plans that did not pass QA, with a low false negative rate.
Keywords quality assurance · beam complexity · radiation therapy
PACS 87.55.Qr · 87.53.Bn · 87.55.-x
1 Introduction
Intensity-modulated radiotherapy techniques (IMRT, including both IMAT and
VMAT) can provide improved dose distributions in treatments of cancerous lesions
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that have concavities or that are close to multiple critical structures [1]. There are,
however, widely recognised disadvantages to treating with unduly complex IMRT
fields [2,3]. Treatments using complex arrangements of small field segments require
longer beam-on time (more MU/Gy) to deliver, resulting in increased risks of pa-
tient movement [2] and increased leakage doses to the patient [3]. Such treatments
also result in increased mechanical stress, increased opportunity for treatment
delivery errors and therefore an increased quality assurance workload [2,4,5].
Generally, the inverse-planning of IMRT treatments requires a compromise
between the need to increase the complexity of the treatment plan, in order to
maximise the conformation of the dose to the target; and the need to limit the
complexity of the treatment plan, in order to maximise the likelihood of accurate
delivery of the planned dose within a reasonable time frame [5,6]. Contemporary
radiotherapy treatment planning systems use cost functions, incorporating various
treatment plan complexity metrics, for optimising the conformity and complexity
of IMRT plans [7–9]. The use of similar metrics to evaluate the complexity of opti-
mised IMRT treatment plans has been investigated by other authors [9,10]. Such
post-processing of IMRT treatment plans has the potential to provide planners
with information on the complexity of a given plan, in relation to the achievable
complexity of treatments to the same site [3,9,11].
Plan evaluation using a metric that is strongly correlated with treatment plan
dosimetric accuracy could also reduce the time required for pre-treatment quality
assurance (QA) measurements and the delay before re-planning of undeliverable
treatments, by identifying IMRT plans that are likely to fail their QA tests. The
development of such a metric requires a broadening of the narrow definition of
‘complexity’ as fluence variability, used in the development of early complexity
metrics [3,11,12]. Dosimetric studies have suggested that the potential for a given
plan to be accurately delivered can also depend on the accuracy with which MLC
effects are modelled by the treatment planning system, the proportion of the treat-
ment that is delivered using low-MU segments, the size and location of individual
beam apertures and the differences in area between the field apertures defined by
the jaws and the (smaller) apertures defined by the MLC [4,5,13]. McNiven et al.
developed the ‘modulation complexity score’ (MCS) as an attempt to incorporate
the effects of fluence map complexity and MLC-aperture complexity within one
metric [5]. While the MCS was shown to be capable of distinguishing between the
levels of complexity required for planning treatments to different sites [5] and has
shown potential for distinguishing between IMRT plans optimised with different
levels of fluence smoothing [10], this metric has not been found to correlate with
increasing dosimetric error for individual treatment sites [13,14].
In this study, therefore, we attempt to identify a metric that can usefully
distinguish between IMRT beams that pass and fail an array-based QA test. To
this end, we reimplement the modulation index (MI) [6,11] and the fluence map
complexity (FMC) [9] fluence-complexity based metrics, which quantify the level of
modulation of each beam. The sensitivities of the fluence-complexity and aperture-
complexity components of the MCS [5] are investigated. Due to the difficulties
associated with obtaining accurate dose calculations for small field apertures [15,
16], the potential for MLC leaf transmission to vary with field size [4] and the
increased uncertainty associated with calculations of dose away from the beam’s
central axis [17,18], we also evaluate novel metrics designed to be sensitive to these
effects. Specifically, we have produced metrics that describe the sizes of the MLC
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apertures (mean field area, MFA, and small-aperture score, SAS), the proportion
of closed leaves within the jaw-defined fields (closed leaf score, CLS) and the
displacement of the MLC apertures, across the central axis (cross-axis score, CAS,
and mean aperture displacement, MAD).
This study aims to identify a metric that can be reliably used to identify
treatment plans that are unlikely to pass pre-treatment QA tests, with the goal of
potentially improving the efficiency and reliability of the IMRT treatment planning
and delivery process.
The initialisms used in this paper are summarised, for reference, in the Ap-
pendix.
2 Methods
2.1 Treatment plans
The QA results for 122 IMRT beams from 18 prostate treatments planned and
delivered over a 6 month period, using the Brainlab iPlan treatment planning
system and Brainlab m3 micro-MLC (Brainlab, Feldkirchen, Germany) are in-
cluded in this study. All treatments were for localised adenocarcenoma, with no
nodal involvement and no metastasis. The IMRT fields had an average of 46 con-
trol points (23 beam segments) per beam, which were delivered in step-and-shoot
mode. For each field, the linear accelerator’s orthogonal jaws were fitted to the
maximum lateral micro-MLC positions and remained stationary throughout the
beam delivery.
Pre-treatment quality assurance measurements were obtained using a Map-
Check2 diode array (Sun Nuclear Corporation, Melbourne, USA), positioned with
its active layer at the isocentre, under 5 cm water-equivalent thickness of plastic.
All beams were delivered from a zero gantry angle, but collimator rotations were
preserved as per the treatment plans. Plans were passed and approved for treat-
ment if 90% of measurement points (above a threshold of 10% of the maximum
dose) resulted in γ(2%, 2mm) < 1.0 or if 95% of measurement points resulted
in γ(3%, 3mm) < 1.0, when compared with dose to the measurement plane cal-
culated by the treatment planning system. Plans that did not meet these criteria
were failed. (Ion chamber measurements were also obtained, to verify planned dose
outputs, but these are not discussed in this study.)
Figure 1 shows a histogram of the MapCheck2 γ pass rates obtained for the
122 beams used in this study. While most beams passed the 90% threshold for the
2%,2mm criteria, 8 beams passed only when the 3%,3mm criteria was used, and 20
beams belonged to plans that failed the QA test. The range of γ(2%, 2mm) < 1.0
pass rates across these treatment plans (65 to 100%) provides a useful sample for
comparison with beam complexity metrics.
Treatment plans were exported from the treatment planning system, in DICOM-
RT format, and analysed using the in-house TADA (Treatment and Dose Assessor)
software, adapted from the existing MCDTK (Monte Carlo DICOM tool-kit) code
[19,20]. The TADA software has previously been used to retrospectively exam-
ine dosimetric quality for large numbers of patient treatments [21]. The modified
TADA code allowed the batch calculation of several established and novel beam
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Fig. 1 Histogram of gamma pass rates for individual beams from plans that were defined as
‘passed’ (black columns) and from plans that were defined as ‘failed’ (white columns).
complexity metrics on a per-plan and per-beam basis, for evaluation against QA
pass rates.
Mean complexity metrics for the group of plans that passed QA and the group
of plans that failed QA were calculated. F-statistic values were calculated under
the null hypothesis that there was no significant linear correlation between metrics
and γ pass rates, as the ratio of the regression sum of squares and residual sum
of squares for linear least squares regression. Corresponding p-values, representing
the probability of a larger F-statistic value occurring by chance, were also cal-
culated. The Sˇida´k correction was used to determine a significance level for each
comparison from a familywise error rate, α, of 0.05, in order to compensate for
multiple comparisons.
2.2 Established metrics
Two complexity metrics calculated using intensity fluence maps were implemented:
the modulation index (MI) proposed by Webb [6] and the fluence map complexity
(FMC) proposed by Llacer et al. [9]. These implementations required the gener-
ation of intensity fluence maps using the beam arrangement data contained in
the RTPLAN DICOM exports. The leaf and jaw positions of each segment in the
beam were used to calculate transmission on a 160 × 160 beam element (bixel)
map representing a possible 40 × 40cm2 field at isocentre. Where the collimators
moved between beam control points the collimator positions were interpolated for
100 steps. The default leaf transmission was assumed to be 1%, approximating val-
ues reported in the literature [22,23]. The intensity maps were generated without
consideration of collimator rotation.
The calculation of MI involved the comparison of deviations among adjacent
bixels in a spectrum of the intensity fluence map to the standard deviation (σ1)
of the intensity fluence map. The calculation method presented by Nicolini et al.
[11] was utilised:
MI(F ) =
∫ F
0
[Zx(f) + Zy(f) + Zxy(f)]
3
df (1)
where each Z spectra are the fraction of changes among adjacent bixels in the
X, Y and X-Y directions that exceed fσ1. An integration limit of F=1 was used
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for the values presented in this work. The calculation of MI values has previously
been implemented in the clinical EPID dosimetry QA software ‘Epiqa’ (EPIdos,
Bratislava, Slovakia) [24]. It has been shown that MI has a monotonic relationship
with dose conformality [6].
This FMC metric is a root sum of differences between fluence bixels (aj) and
lateral neighbouring bixels, normalised to the sum of each bixel:
FMC =
1∑
j
aj
√√√√√∑
j

aj − λk ∑
k∈Nj
ak


2
(2)
where λk is the weight assigned to the change between neighbouring bixels (0.5
where a bixel has 2 lateral neighbours). A FMC value of 0 would indicate that
there are no changes in bixel intensity between lateral bixels, while a value of 1
would imply a chequerboard pattern.
The modulation complexity score (MCS) proposed by McNiven et al. [5] was
also implemented. The MCS metrics characterises modulation with two parame-
ters: aperture area variability (AAV), the difference between leaf pair apertures
for any segment compared to the maximum leaf separation in the beam; and leaf
sequence variability (LSV), the variation between adjacent leaves in the same leaf
bank. A high MCS value indicates little modulation of the beam intensity. The
MCS metric was developed to assess plan deliverability by correlation with Map-
Check gamma pass rates [5].
2.3 Novel metrics
An additional five new metrics were developed for the TADA code. These novel
metrics are conceptually and computationally simpler than the established MI,
FMC and MCS metrics. They were primarily designed to be sensitive to the treat-
ment plan parameters that are most likely to compromise accurate dose calcu-
lations; small field and small segment aperture sizes [15,16], closed MLC leaves
below open linac jaws [4], and small field segments delivered from off-axis positions
[17,18].
The mean field area (MFA) was calculated as a weighted mean of the area
between exposed open leaf pairs for all segments of the beam, each weighted ac-
cording to the number of MU delivered:
MFAbeam =
I∑
i=1
Ai ×
MUi
MUbeam
(3)
where I is the number of segments in the beam and A is the aperture area between
opposing leaves.
The small aperture score (SAS) was calculated as the ratio of open leaf pairs
where the aperture was less than a defined criteria (2, 5, 10 and 20 mm in this
study) to all open leaf pairs:
SAS(x)beam =
I∑
i=1
N(x > a > 0)i
N(a > 0)i
×
MUi
MUbeam
(4)
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where x is the aperture criteria, I is the number of segments in the beam, N is the
number of leaf pairs not positioned under the jaws, and a is the aperture distance
between opposing leaves.
The closed leaf score (CLS) was calculated as the ratio of closed leaf pairs to
all leaf pairs inside the jaw-defined field:
CLSbeam =
I∑
i=1
N(a 6= 0)i
Ni
×
MUi
MUbeam
(5)
where I is the number of segments in the beam, N is the number of leaf pairs not
positioned under the jaws, and a is the aperture distance between opposing leaves.
The cross-axis score (CAS) was calculated as the ratio of leaf pairs where a
leaf crosses the “0” position aligned with the central beam axis to all open leaf
pairs:
CASbeam =
I∑
i=1
N(a > m)i
N(a > 0)i
×
MUi
MUbeam
(6)
where I is the number of segments in the beam, N is the number of leaf pairs
not positioned under the jaws, a is the aperture distance between opposing leaves
and m is the centre of the aperture distance between opposing leaves (where 0
indicates alignment with the central beam axis).
These SAS, CLS and CAS values were calculated for each segment of the beam,
and a weighted average calculated according to the number of MU delivered in each
segment. A value of 1 indicates all leaf pairs inside the jaw-defined field have either
an aperture less than the given criteria, are closed, or cross the axis, respectively.
The mean asymmetry distance (MAD) is the weighted average of the distance
between of the centre of every open leaf pair aperture m and the central beam
axis:
MADbeam =
I∑
i=1
(
J∑
j=1
|mj |
)
×
MUi
MUbeam
(7)
where I is the number of segments in the beam, J is the number of leaves in each
opposing bank, and m is the centre of the aperture distance between opposing
leaves (where 0 indicates alignment with the central beam axis).
3 Results
Table 1 shows the calculated mean beam complexity metrics for the beams in plans
that passed and failed QA testing. There were 4 metrics which statistics suggested
could be useful in predicting MapCheck pass rates: MI, MFA, and SAS for 5mm
and 10mm.
Figures 2(a), (b), (c) and (d) respectively show the calculated MI, FMC, MCS
and AAV values (that is, the established metric values) for the prostate fields
examined in this study, plotted against the proportion of points that resulted in
γ(2%, 2mm) < 1.0 when MapCheck2 measurement results were compared with
dose planes from the treatment planning system.
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Table 1 Summary of mean plan complexity metrics for plans that passed (Meanpass) and
failed (Meanfail) QA testing. F statistic tests for significant linear relationship between the
metric and γ pass rates. Critical F statistic values were 3.92 for α = 0.05, 6.85 for α = 0.01,
and 11.38 for α = 0.001. The p-value represents the probability of a larger F statistic occurring
by chance. Significant F statistic values (α = 0.0025, after Sˇida´k correction to experiment-wide
α = 0.05) are shown in boldface type.
Metric Meanpass Meanfail F value p value
MCS 0.37 ± 0.05 0.35 ± 0.05 0.140 0.646
AAV 0.49 ± 0.06 0.47 ± 0.06 0.097 0.756
LSV 0.75 ± 0.02 0.75 ± 0.02 0.506 0.478
MI 0.012 ± 0.002 0.015 ± 0.002 11.397 0.001
FMC 0.008 ± 0.001 0.008 ± 0.001 0.002 0.965
MFA 1300 ± 200 1200 ± 200 5.439 0.021
SAS (2mm) 0.17 ± 0.06 0.21 ± 0.03 3.117 0.080
SAS (5mm) 0.19 ± 0.06 0.25 ± 0.03 9.918 0.002
SAS (10mm) 0.26 ± 0.07 0.32 ± 0.05 6.163 0.014
SAS (20mm) 0.50 ± 0.09 0.56 ± 0.07 2.984 0.087
CLS 0.10 ± 0.04 0.12 ± 0.05 0.346 0.558
CAS 0.65 ± 0.09 0.68 ± 0.08 1.818 0.180
MAD 20 ± 4 21 ± 4 0.859 0.356
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Fig. 2 (a) - (d): Treatment plan metrics evaluated using established methods ((a) MI, (b)
FMC, (c) MCS and (d) AAV) plotted against QA results (proportion of points satisfying
γ(2%, 2mm) < 1.0) for beams from plans that passed their QA assessment (filled data points)
and plans that failed their QA assessment (open data points). Linear regression used for trend
line.
The slope of the trend line for the calculated MI values is significantly different
to zero (p = 0.001), implying correlation, while no significant correlation was
observed between γ(2%, 2mm) < 1.0 and FMC, MCS and AAV values.
Figures 3(a), (b), (c) and (d) respectively show the calculated MFA, MAD,
CAS and CLS values (that is, the novel metric values) for the prostate fields
examined in this study, plotted against the proportion of points that resulted
8 Crowe et al.
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Fig. 3 (a) - (g): Treatment plan metrics evaluated using simple, novel methods ((a) MFA,
(b) MAD, (c) CAS, (d) CLS, (e) SAS for each beam, where the small aperture is defined as 2
mm, (f) SAS for each beam, where the small aperture is defined as 10 mm, (g) SAS for entire
treatment plans, where the small aperture is defined as 10 mm) plotted against QA results
(proportion of points satisfying γ(2%, 2mm) < 1.0) for beams from plans that passed their QA
assessment (filled data points) and plans that failed their QA assessment (open data points).
(h): SAS threshold value (filled data points) and false negative rate (open data points) plotted
against defined small aperture size. Linear regression used for trend line.
in γ(2%, 2mm) < 1.0 when MapCheck2 measurement results were compared with
dose planes from the treatment planning system. Figures 3(e), (f), (g) and (h) show
results of specifically investigating the proportion of small segment apertures that
are used in each treatment (SAS scores, definitions, thresholds and false-negative
rates).
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The slope of the trend line for the SAS5 metric was significantly different to
zero (p ≈ 0.002). There were 2 novel metrics for which correlation with γ pass rates
was potentially significant: MFA and SAS10 (p ≈ 0.02 and p ≈ 0.01 respectively).
No significant correlation between the calculated values of the MAD, CAS, CLS,
SAS2 and SAS20 metrics and γ pass rates was suggested by the calculated p-values
(see table 1).
4 Discussion
4.1 Established metrics
Figure 2(a) suggests that MI is significantly correlated with plan dosimetric accu-
racy (p < 0.01 for trend line), with a 10% decrease in MI leading to an average
20% increase in the proportion of points satisfying γ(2%, 2mm) < 1.0. This is sup-
ported by the significance of variation in table 1. However, figure 2(a) also shows a
strong overlap between the MI values of beams from plans that passed and failed
their QA tests; there is no value of MI above which all plans have poor gamma
evaluation results.
No relationship between FMC and QA result appears in the data shown in
figure 2(b), where FMC values have a small range (0.006 - 0.011) and show no
systematic variation with the gamma evaluation results. Comparison of this result
with the MI result in figure 2(a) suggests that the local variation in the intensity
of beamlets is relatively consistent across these prostate plans, and that the MI
result is therefore dominated by the differences in whole-beam standard deviations
between the different treatment plans.
The MCS data shown in figure 2(c) is not significantly correlated to QA results.
Table 1 did not suggest a significant difference between the plans that failed QA
(open data points) and the plans that passed QA (filled data points), and a strong
overlap between the data sets can be observed. The MCS values shown in figure
2(c) suggest that the plans evaluated here are, on average, more complex than the
prostate plans previously reported by McGarry et al. [10], which were themselves
more complex than the prostate plans reported by McNiven et al. [5].
Figure 2(d) shows AAV data that are quantitatively different but qualitatively
similar to the MCS data in figure 2(b). As noted in section 2.2, the MCS for a given
beam is the product of LSV and AAV. For the prostate treatments studied here, the
LSV is relatively constant across all beams, with a mean value of 0.75± 0.02. The
variation in the MCS results between beams, shown in Figure 2(b), is therefore
largely determined by the variation in AAV. Figures 2(c) and (d) show results
for individual beams, but MCS, LSV and AAV were also evaluated for entire
treatments, producing results (not shown) similar to these individual beam results.
The results of our specific examination of the effect of beam aperture size on
dosimetric accuracy are discussed in the following section.
4.2 Novel metrics
Figure 3(a) suggests that MFA is potentially correlated with plan dosimetric ac-
curacy (p ≈ 0.02), with a 10% increase in MFA leading to an average 50% increase
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in the proportion of points satisfying γ(2%, 2mm) < 1.0. This result supports the
expectation that the dose from small micro-collimated IMRT segments is not as
accurately predicted by the treatment planning system as the dose delivered via
larger apertures [15]. However, this correlation between beam segment area and
gamma evaluation result does not provide a threshold MFA value that can be used
to identify plans that are likely to fail QA because, as table 1 and figure 3(a) show,
there is a strong overlap between the MFA values of beams from plans that passed
and failed their QA tests.
The calculated MAD and CAS values, shown in figures 3(b) and (c), are not
significantly correlated to the QA pass rates, and it is not possible to unambigu-
ously identify plans that failed their QA tests. Both metrics result in a threshold
(16 mm for MAD and 0.52 for CAS) below which all plans pass their QA tests,
but both metrics result in a substantial false-negative rate (more than 50%) above
this threshold. Figure 3(d) shows that a similar metric, quantifying the proportion
of MLC leaves in each beam that are closed beneath open jaws (CLS), does not
produces a useful correlation. Here, there is total overlap between the CLS ranges
of the plans that passed and failed their QA tests. Evidently, all of these prostate
treatments use beam segments with between 5 and 20 % of the MLC leaves closed,
and this has no systematic effect on the QA outcomes.
By contrast, figure 3(e) and (f) show that less equivocal results can be achieved
when the proportion of segment apertures defined as ‘small’ (SAS) is computed
(p ≈ 0.002 and p ≈ 0.01 respectively). Figure 3(e) shows the result when a small
aperture is defined as one where the MLC leaf separation is less than 5 mm and
figure 3(f) shows the result when a small aperture is defined as one where the
MLC leaf separation is less than 10 mm. All small aperture definitions used in this
study resulted in similar results; increasing dosimetric accuracy is correlated with
decreasing proportion of small apertures. The 10 mm result shown in figure 3(f),
is the most unequivocal of the beam analysis results and shows a threshold SAS
of 0.27, below which all plans pass their QA tests. Above this threshold, there is
a substantial overlap between the results for beams from plans that passed and
failed their QA tests.
When the SAS is evaluated over entire plans, rather than per beam, results
similar to figure 3(g) are obtained. Figure 3(g) shows the result when the small
aperture is defined as one where the MLC leaf separation is less than 10 mm. In
this figure, all plans with SAS below the threshold of 0.27 pass their QA tests.
Above this threshold, only 2 of the 15 plans that passed their QA tests are grouped
with the plans that failed. If the SAS, using the 10 mm small aperture definition
and a threshold value of 0.27, was used to evaluate these plans before QA, it would
identify all of the failed plans and 2 out of the 15 passed plans as likely to fail QA.
Figure 3(h) shows (as filled data points) the thresholds, SAS values below which
all plans passed their QA tests, resulting from evaluating the SAS using a range of
different definitions of a ‘small aperture’. This threshold increases approximately
linearly with increasing small aperture definition. Figure 3(h) also shows (as open
data points) the false negative rates (number of passed plans grouped with the
failed plans, above the threshold / total number of passed plans) for the different
small field definitions and thresholds. The false negative rate is relatively high when
the small aperture is defined as 1 mm, but decreases to a minimum when the small
aperture is defined as 5 - 10 mm, and then increases again as the definition of the
small aperture is further increased. Use of 10 mm as the ‘small aperture’ definition
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is advantageous because it falls into a broad minima in the false-negative curve; 10
mm is not so small that such apertures are contained in many segments of many
beams and is not so large that it becomes less useful for identifying apertures
where the treatment planning system’s dose calculation is questionable.
5 Conclusions
This study evaluated some new and established IMRT treatment plan complexity
metrics, with a view to identifying which of them might be useful for identifying
likely QA failures and thereby improving the efficiency of the IMRT treatment
planning and delivery process. A statistically significant correlation was identified
between MI and γ pass rates. However, there was substantial overlap between the
MI values of the beams that passed and failed their QA tests, limiting the utility
of this metric as a treatment plan evaluation tool.
Several of the novel metrics evaluated in this study (specifically, the MAD, CAS
and CLS) failed to show a statistically significant correlation with γ pass rate or
provide a means to identify the likelihood of QA success, despite quantifying beam
properties that were expected to affect dose calculation accuracy.
By contrast, the SAS metrics, which describe the proportion of small MLC
apertures in each beam, were found to be well correlated with γ pass rates (par-
ticularly when the ‘small’ aperture was defined as an MLC separation of 5 mm)
and provided threshold values below which all plans passed their QA tests, and
above which only a small number of passing plans were identified as likely to fail.
While this outcome should be immediately useful to radiotherapy centres where
prostate IMRT treatments are planned and delivered using the Brainlab system
and tested using the MapCheck2 diode array, these results also suggest avenues
for further investigation at centres where IMRT treatments are delivered to other
sites or using other systems. The TADA software is able to process treatment plans
exported in the DICOM-RT format from a wide range of planning systems. The
usefulness of fluence map complexity metrics may vary between treatment sites
and inverse-planning optimisation systems, with the variability of each metric
depending on the degree of local (FMC) or global (MI) beam fluence modulation.
Further development or investigation of novel treatment plan complexity metrics
should concentrate on metrics that describe the beam aperture size (MFA, SAS)
rather than the beam aperture position (MAS, CAS).
Appendix: Summary of initialisms
– AAV: Aperture area variability
– CAS: Cross axis score
– CLS: Closed leaf score
– FMC: Fluence map complexity
– LSV: Leaf sequence variability
– MAD: Mean aperture displacement
– MCDTK: Monte Carlo DICOM tool-kit
– MCS: Modulation complexity score
– MFA: Mean field area
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– MI: Modulation index
– SAS: Small aperture score
– TADA: Treatment and dose assessor
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